In NYC, life sciences are thriving in the midst of COVID-19, never closing. Even as some of its resident companies began pivoting into new areas, NYC's life science ecosystem never closed. Even as some of its resident companies began pivoting into new areas, NYC's life science ecosystem remained resilient, driving innovation and creating new opportunities. From federally funded research to venture-backed startups, the city's biotech companies continued to grow and thrive.

### FEATURED SPEAKERS

#### 1:05 PM - 1:50 PM

**Dr. Asaf Zviran (CEO & CSO):** Co-inventor of the technology used by C2i. Asaf led the company’s development from research concept to VC backed early stage startup. Asaf brings over 15 years of R&D experience in academia and industry, as well as management positions in large organizations (IDF, IAI) and startups. As a former cancer survivor, Asaf is passionate about applying his scientific knowledge and expertise to develop innovative solutions for cancer patients.

**Shara Ticku (Managing Director, C16 Biosciences):** Shara is a molecular biologist by training, with scientific experience both in academia and industry. Prior to founding C16 Biosciences, Shara worked at Goldman Sachs, the Clinton Health Access Initiative, and the United Nations. She holds an MBA from Harvard Business School and a BA/Sc in Physics and Biology from the University of Toronto. Shara is a food systems engineer and she believes in the potential to cure human disease and improve quality of life or facilitating ways that we can feed, fuel and heal the world through technological innovation in biology. NJK+A is committed to delivering dynamic, actionable solutions for scientific and medical breakthroughs.

**Laura Katz (Founder & CEO, Helaina):** Laura is a Food Scientist and the Founder and CEO of Helaina. Helaina is a biotech company developing a palm oil alternative for consumer products, raised $12 million to fund the development and clinical validation of C2i Genomics’ personalized, next generation solution for monitoring recurrence and treatment response of various types of solid cancers. Join NYC Builds Bio+ executives and investors from BioLabs@NYULangone, C16 Biosciences, Helaina, and NYC Life Sciences to discuss the exciting progress being made toward next-level bio-based products, treatments and drugs in the midst of COVID-19.

### AGENDA

10:00 AM - 10:45 PM  Welcome & Overview of the Meeting

10:45 AM - 11:30 PM  Panel Presentation: NYC’s Life Sciences Thriving in the Midst of COVID-19

- Dr. Asaf Zviran (CEO & CSO, C2i Genomics)
- Shara Ticku (CEO & Founding Partner, C16 Biosciences)
- Laura Katz (CEO, Helaina)

11:30 AM - 11:45 AM  Q&A with Audience